64th ASH Annual Meeting and Exposition: 903. Health Services and Quality

Symposia: Health Services and Quality–Myeloid Malignancies Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Biological therapies, adult, Lymphoid Leukemias, ALL, MDS, clinical trials, Clinical Practice (Health Services and Quality), elderly, Translational Research, Non-Biological therapies, Clinical Research, health outcomes research, Chemotherapy, health disparities research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, pediatric, patient-reported outcomes, Diseases, Therapies, therapy sequence, Adverse Events, Lymphoid Malignancies, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Transplantation, machine learning

388-390 (Ernest N. Morial Convention Center)

Moderators:

Thomas G. Knight, MD, Levine Cancer Institute, Atrium Health and Rachel J. Cook, MD, Oregon Health and Science University

Disclosures:

No relevant conflicts of interest to declare.

9:30 AM

127

Analysis of 372 Adult Allograft Recipients Reveals Associations between Non-European Ancestry, Low Socioeconomic Status, and Receipt of HLA-Disparate Grafts

Warren B Fingrut, MD¹, Stephanie Chinapen¹^*, Angela Katrichis¹^*, Caroline Carino¹^*, Eric Davis, MPH¹^*, Brian C. Shaffer, MD^1,2, Christina Cho, MD^1,2, Gunjan L. Shah, MD^1,3^* and Juliet N. Barker, MBBS^1,3

¹Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Medicine, Weill Cornell Medical College, New York, NY
³Weill Cornell Medicine, New York, NY

9:45 AM

128

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Kyle R Wiatrowski, MD/MBA Candidate¹, Pragya Srivastava, PhD¹^*, Alan Hutson, PhD²^*, Hana Golding, PhD³^*, Surender Khurana, PhD³^*, Lisa King⁴^*, Jody Manischewitz³^*, Molly Sheehan⁵^*, Pankit Vachhani, MD⁶, Amanda Przespolewski, DO¹, James E. Thompson, MD⁷, Eunice S. Wang, MD¹, Michael J Nemeth, PhD⁵ and Elizabeth A. Griffiths, MD¹

¹Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
²Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
³Center For Biologics Evaluation and Research, U. S. Food and Drug Administration, Bethesda, MD
⁴Center For Biologics Evaluation and Research, U. S. Food and Drug Administration, Rockville, MD
⁵Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁶O’ Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL
⁷Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

10:00 AM

129

Toxicity Reporting Is Inconsistent and Incomplete, and Subjective Minimizing Language Is Common in Acute Leukemia Clinical Trials: A Systematic Review of Randomized Controlled Trials Presented at ASH between 2017-2021

Benjamin Chin-Yee, MD, FRCPC, MA^1,2, Turab Mohammed, MD³, Clarissa Skorupski, MD⁴, Bishal Gyawali, MD, PhD⁵^*, Gary H. Lyman, MD^6,7,8, Lisa K. Hicks, MD, MSc#^9,10 and Dr. Nicole M. M. Kuderer, MD, MSc¹¹

¹Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada
²Division of Hematology, Department of Medicine, Schulich School of Medicine, Western University, London, ON, Canada
³Moffitt Cancer Center, Tampa, FL
⁴Department of Medicine, University of Toronto, Toronto, ON, Canada
⁵Department of Oncology, Queen's University, Kingston, ON, Canada
⁶Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁷Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Department of Medicine, University of Washington School of Medicine, Seattle, WA
⁹Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada
¹⁰Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada
¹¹Advanced Cancer Research Group, Seattle, WA

10:15 AM

130

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia

Jan Philipp Bewersdorf, MD¹, Kishan K Patel, MD MHS²^*, George Goshua, MD, MSc^3,4, Rory M. Shallis, MD^5,6, Nikolai A. Podoltsev, MD, PhD^5,7, Maximilian F. Stahl, MD⁸, Jessica M. Stempel, MD⁹, Eytan Stein, MD¹⁰, Scott F. Huntington, MD, MPH^5,11 and Amer M. Zeidan, MD^5,11

¹Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA
³Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA
⁴Section of Hematology, Yale University School of Medicine, New Haven, CT
⁵Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT
⁶Department of Internal Medicine, School of Medicine and Yale Cancer Center, Yale University, New Haven, CT
⁷Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT
⁸Department of Medical Oncology, Dana-Farber Institute, Boston, MA
⁹Department of Medicine; Section of Hematology, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, CT
¹⁰Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT

10:30 AM

131

Machine Learning Approaches Incorporating High-Dimensional Longitudinal Data Improve the Prediction of Survival after Allogeneic Hematopoietic Cell Transplantation

Yiwang Zhou, PhD¹^*, Jesse Smith, MPH¹^*, Dinesh Keerthi, MSEE, MBA²^*, Suraj Sarvode Mothi, MPH¹^*, David C. Shyr, MD³^*, Barbara Spitzer, MD⁴, Avijit Chatterjee, PhD⁵^*, Subrata Chatterjee, PhD⁵^*, Swati Naik, MBBS⁶, Li Tang, PhD¹^* and Akshay Sharma, MBBS²

¹Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
²Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN
³Department of Pediatrics/Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA
⁴Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
⁵DigITs—Digital, Informatics and Technology Solutions, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TX

10:45 AM

132

A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study

Marissa Locastro, BS¹, Chandrika Sanapala, MS²^*, Ying Wang, MS³^*, Marielle Jensen-Battaglia, PT, DPT³^*, Marsha Wittink, MD, MBE⁴^*, Sally Norton, PhD, RN, FNAP, FPCN, FAAN⁵^*, Heidi Klepin, MD⁶, Daniel R. Richardson, MD, MSc, MA⁷, Jason H. Mendler, MD, PhD⁸, Jane L. Liesveld, MD⁹, Eric J. Huselton, MD⁹, Kristen M. O'Dwyer, MD⁸, Ashley-Marie Cortes, BS¹^*, Chrystina Rodriguez, BS³^* and Kah Poh (melissa) Loh, MD⁹

¹School of Medicine and Dentistry, University of Rochester, Rochester, NY
²Burrell College of Osteopathic Medicine, Las Cruces
³University of Rochester Medical Center, Rochester
⁴Department of Psychiatry, University of Rochester Medical Center, Rochester, NY
⁵School of Nursing, University of Rochester Medical Center, Rochester
⁶Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston Salem, NC
⁷Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
⁸Wilmot Cancer Institute, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY
⁹Wilmot Cancer Institute, University of Rochester Medical Center, Rochester

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

903.O1.6 903. Health Services and Quality—Myeloid Malignancies I